CareDx, Inc (NASDAQ:CDNA) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC lessened its holdings in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 69.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,118 shares of the company's stock after selling 22,540 shares during the quarter. Lazard Asset Management LLC's holdings in CareDx were worth $216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of CDNA. Divisadero Street Capital Management LP purchased a new position in shares of CareDx during the 4th quarter worth $15,239,000. Jacobs Levy Equity Management Inc. boosted its stake in shares of CareDx by 52.6% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,243,580 shares of the company's stock worth $26,625,000 after acquiring an additional 428,864 shares during the last quarter. Bamco Inc. NY boosted its stake in shares of CareDx by 17.6% during the 4th quarter. Bamco Inc. NY now owns 2,207,299 shares of the company's stock worth $47,258,000 after acquiring an additional 330,627 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of CareDx by 7.1% during the 4th quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company's stock worth $104,047,000 after acquiring an additional 323,554 shares during the last quarter. Finally, Intrinsic Edge Capital Management LLC purchased a new position in shares of CareDx during the 4th quarter worth $5,460,000.

CareDx Stock Performance

CareDx stock traded up $0.68 during trading hours on Tuesday, hitting $17.63. The company had a trading volume of 1,378,386 shares, compared to its average volume of 896,883. The firm has a market cap of $981.66 million, a P/E ratio of -6.53 and a beta of 2.27. CareDx, Inc has a 1 year low of $12.90 and a 1 year high of $34.84. The company has a 50-day moving average price of $17.44 and a two-hundred day moving average price of $20.66.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $84.69 million during the quarter, compared to analysts' expectations of $84.56 million. During the same quarter in the prior year, the company earned ($0.03) EPS. The company's revenue was up 17.6% compared to the same quarter last year. As a group, equities research analysts anticipate that CareDx, Inc will post -0.9 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CDNA. Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. The Goldman Sachs Group reduced their price target on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Stephens reissued an "overweight" rating and issued a $40.00 price objective on shares of CareDx in a research report on Monday, May 5th. Finally, HC Wainwright reissued a "neutral" rating and issued a $25.00 price objective on shares of CareDx in a research report on Monday, May 5th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $30.33.

Insider Activity

In related news, Director Peter Maag sold 13,281 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total transaction of $228,831.63. Following the completion of the transaction, the director now owns 316,743 shares in the company, valued at $5,457,481.89. The trade was a 4.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christine Cournoyer sold 16,700 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total transaction of $235,971.00. Following the transaction, the director now owns 37,045 shares of the company's stock, valued at approximately $523,445.85. This trade represents a 31.07% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 59,382 shares of company stock worth $934,509. Corporate insiders own 4.90% of the company's stock.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.